Switch theme
Sign up to access all valuation multiples
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
1982
730
LTM Revenue $243M
LTM EBITDA $57.2M
$704M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mesa Laboratories has a last 12-month revenue (LTM) of $243M and a last 12-month EBITDA of $57.2M.
In the most recent fiscal year, Mesa Laboratories achieved revenue of $241M and an EBITDA of $42.3M.
Mesa Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mesa Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $243M | XXX | $241M | XXX | XXX | XXX |
| Gross Profit | $152M | XXX | $151M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $57.2M | XXX | $42.3M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $57.1M | XXX | $16.3M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $1.3M | XXX | -$2.0M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $151M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mesa Laboratories's stock price is $101.
Mesa Laboratories has current market cap of $549M, and EV of $704M.
See Mesa Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $704M | $549M | XXX | XXX | XXX | XXX | $10.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mesa Laboratories has market cap of $549M and EV of $704M.
Mesa Laboratories's trades at 3.0x EV/Revenue multiple, and -25.3x EV/EBITDA.
Equity research analysts estimate Mesa Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mesa Laboratories has a P/E ratio of 429.0x.
See valuation multiples for Mesa Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $549M | XXX | $549M | XXX | XXX | XXX |
| EV (current) | $704M | XXX | $704M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.3x | XXX | -25.3x | XXX | XXX | XXX |
| EV/EBIT | 12.3x | XXX | 54.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 429.0x | XXX | -8.4x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMesa Laboratories's last 12 month revenue growth is 4%
Mesa Laboratories's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Mesa Laboratories's rule of 40 is -7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mesa Laboratories's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mesa Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | -12% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -7% | XXX | -7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mesa Laboratories acquired XXX companies to date.
Last acquisition by Mesa Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Mesa Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mesa Laboratories founded? | Mesa Laboratories was founded in 1982. |
| Where is Mesa Laboratories headquartered? | Mesa Laboratories is headquartered in United States of America. |
| How many employees does Mesa Laboratories have? | As of today, Mesa Laboratories has 730 employees. |
| Who is the CEO of Mesa Laboratories? | Mesa Laboratories's CEO is Mr. Gary M. Owens. |
| Is Mesa Laboratories publicy listed? | Yes, Mesa Laboratories is a public company listed on NAS. |
| What is the stock symbol of Mesa Laboratories? | Mesa Laboratories trades under MLAB ticker. |
| When did Mesa Laboratories go public? | Mesa Laboratories went public in 1995. |
| Who are competitors of Mesa Laboratories? | Similar companies to Mesa Laboratories include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Mesa Laboratories? | Mesa Laboratories's current market cap is $549M |
| What is the current revenue of Mesa Laboratories? | Mesa Laboratories's last 12 months revenue is $243M. |
| What is the current revenue growth of Mesa Laboratories? | Mesa Laboratories revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Mesa Laboratories? | Current revenue multiple of Mesa Laboratories is 2.9x. |
| Is Mesa Laboratories profitable? | Yes, Mesa Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mesa Laboratories? | Mesa Laboratories's last 12 months EBITDA is $57.2M. |
| What is Mesa Laboratories's EBITDA margin? | Mesa Laboratories's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Mesa Laboratories? | Current EBITDA multiple of Mesa Laboratories is 12.3x. |
| What is the current FCF of Mesa Laboratories? | Mesa Laboratories's last 12 months FCF is $41.7M. |
| What is Mesa Laboratories's FCF margin? | Mesa Laboratories's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Mesa Laboratories? | Current FCF multiple of Mesa Laboratories is 16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
